Skip to main content
main-content

12.02.2019 | Original Article

Association of Genetic Polymorphisms in the Beta-1 Adrenergic Receptor with Recovery of Left Ventricular Ejection Fraction in Patients with Heart Failure

Zeitschrift:
Journal of Cardiovascular Translational Research
Autoren:
Jasmine A. Luzum, Joseph D. English, Umair S. Ahmad, Jessie W. Sun, Benjamin D. Canan, Wolfgang Sadee, Joseph P. Kitzmiller, Philip F. Binkley
Wichtige Hinweise
Associate Editor Paul J. R. Barton oversaw the review of this article

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1007/​s12265-019-09866-5) contains supplementary material, which is available to authorized users.
Dedication
In sorrow, we would like to dedicate this work to our friend and co-author, Joseph P. Kitzmiller. Dr. Kitzmiller passed away on October 3, 2018, shortly before our submission of this paper.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Abstract

Two common genetic polymorphisms in the beta-1 adrenergic receptor (ADRB1 Ser49Gly [rs1801252] and Arg389Gly [rs1801253]) significantly affect receptor function in vitro. The objective of this study was to determine whether ADRB1 Ser49Gly and Arg389Gly are associated with recovery of left ventricular ejection fraction (LVEF) in patients with heart failure. Patients with heart failure and baseline LVEF ≤ 40% were genotyped (n = 98), and retrospective chart review assessed the primary outcome of LVEF recovery to ≥ 40%. Un/adjusted logistic regression models revealed that Ser49Gly, but not Arg389Gly, was significantly associated with LVEF recovery in a dominant genetic model. The adjusted odds ratio for Ser49 was 8.2 (95% CI = 2.1–32.9; p = 0.003), and it was the strongest predictor of LVEF recovery among multiple clinical variables. In conclusion, patients with heart failure and reduced ejection fraction that are homozygous for ADRB1 Ser49 were significantly more likely to experience LVEF recovery than Gly49 carriers.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Nicht verpassen: e.Med bis 13. März 2019 100€ günstiger im ersten Jahr!

Weitere Produktempfehlungen anzeigen
Zusatzmaterial
ESM 1 (DOCX 17 kb)
12265_2019_9866_MOESM1_ESM.docx
ESM 2 (DOCX 18 kb)
12265_2019_9866_MOESM2_ESM.docx
ESM 3 (DOCX 14 kb)
12265_2019_9866_MOESM3_ESM.docx
Literatur
Über diesen Artikel
  1. Sie können e.Med Innere Medizin 15 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.


 

Neu im Fachgebiet Kardiologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Kardiologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise